Early results from implementation of HIV pre-exposure prophylaxis (PrEP) with long-acting injectable cabotegravir for people with barriers to oral strategies, Italy, December 2024 to August 2025

Between December 2024 and August 2025, two Italian HIV/STI clinics offered long-acting injectable cabotegravir (CAB-LA) for HIV prevention in 265 individuals, representing the first European real-world implementation. Participants were prioritised based on vulnerabilities compromising oral pre-exposure prophylaxis (PrEP), such as poor adherence, comorbidities and behavioural barriers. Adherence to injections exceeded 95%, tolerability was favourable and only 1.5% discontinued for drug-related reasons. These findings demonstrate the feasibility of CAB-LA in European clinical services and support its use in specific populations.

Authors

Institutions

Publication Details

Journal
Eurosurveillance
Published
2025-10-02
DOI
https://doi.org/10.2807/1560-7917.es.2025.30.39.2500739
Citations
2
Primary Topic
HIV/AIDS Research and Interventions
Type
article
Field-Weighted Citation Impact
2.79
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Early results from implementation of HIV pre-exposure prophylaxis (PrEP) with long-acting injectable cabotegravir for people with barriers to oral strategies, Italy, December 2024 to August 2025

G. Del Frate, Davide Moschese, Samuel Lazzarin, V Barchi et al.
2 citations
Eurosurveillance
HIV/AIDS Research and Interventions
2.79
article

Early results from implementation of HIV pre-exposure prophylaxis (PrEP) with long-acting injectable cabotegravir for people with barriers to oral strategies, Italy, December 2024 to August 2025

G. Del Frate, Davide Moschese, Samuel Lazzarin, V Barchi, Maddalena Matone, Sara Passacantilli, Andrea Antinori, Paolo Faccendini, Rozenn Esvan, Damiano Farinacci, D Maddalena, Andrea Gori, Valentina Mazzotta, Agostino Riva, Francesco Caruso, Giulia Micheli, Debora Visigalli, Maria Vittoria Cossu, Alessandro Giacinta, Chiara Fusetti, Giulia Terracini, Giulia Del Duca, Francesco Petri
article en
2 citations

Abstract

Between December 2024 and August 2025, two Italian HIV/STI clinics offered long-acting injectable cabotegravir (CAB-LA) for HIV prevention in 265 individuals, representing the first European real-world implementation. Participants were prioritised based on vulnerabilities compromising oral pre-exposure prophylaxis (PrEP), such as poor adherence, comorbidities and behavioural barriers. Adherence to injections exceeded 95%, tolerability was favourable and only 1.5% discontinued for drug-related reasons. These findings demonstrate the feasibility of CAB-LA in European clinical services and support its use in specific populations.

EurosurveillanceVol. 30(39)
University of Milan (IT), Istituto Nazionale per le Malattie Infettive Lazzaro Spallanzani (IT), Centre for Multidisciplinary Research in Health Science (IT), ASST Fatebenefratelli Sacco (IT)
Openalex Percentile: Top 8%
HIV/AIDS Research and Interventions
2.79
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.